Alterations of the exo- and endometabolite profiles in breast cancer cell lines: A mass spectrometry-based metabolomics approach

Analytica Chimica Acta

Volumn 925, Issue , 2016, Pages 34-42

  Willmann, Lucas ^a   Schlimpert, Manuel ^a   Hirschfeld, Marc ^b,c   Erbes, Thalia ^b   Neubauer, Hans ^d   Stickeler, Elmar ^e   Kammerer, Bernd ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Breast cancer; Liquid chromatography; Mass spectrometry; Metabolomics; Quadrupole time of flight

Indexed keywords

CELL CULTURE; CHROMATOGRAPHY; CYTOLOGY; DISEASES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; SPECTROMETRY;

BREAST CANCER; INTERCONNECTED PATHWAYS; METABOLOMICS; MOLECULAR CHARACTERISTICS; MULTIPLE REACTION MONITORING; QUADRUPOLE-TIME OF FLIGHTS; TANDEM MASS SPECTROMETRY; TRIPLE-NEGATIVE BREAST CANCERS;

CELLS;

1 RIBOSYL NICOTINAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; BT 474 CELL LINE; CANCER CELL CULTURE; CONTROLLED STUDY; ELECTROSPRAY; ENDOMETABOLITE; EXOMETABOLITE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 10A CELL LINE; MDA MB 231 CELL LINE; MDA MB 453 CELL LINE; METABOLITE; MONITORING; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA METABOLISM; STANDARDIZATION; TRIPLE NEGATIVE BREAST CANCER; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BREAST TUMOR; CLUSTER ANALYSIS; FEMALE; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER ANALYSIS; FEMALE; HUMANS; MASS SPECTROMETRY; METABOLOMICS;

EID: 84992311400     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2016.04.047     Document Type: Article

References (47)

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int. J. Cancer 2015, 136:E359-E386. 10.1002/ijc.29210.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5:5-23. 10.1016/j.molonc.2010.11.003.
4. Hu X., Stern H.M., Ge L., O'Brien C., Haydu L., Honchell C.D., et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 2009, 7:511-522. 10.1158/1541-7786.MCR-08-0107.
5. Holliday D.L., Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 13:215. 10.1186/bcr2889.
6. Armitage E.G., Barbas C. Metabolomics in cancer biomarker discovery: Current trends and future perspectives. J. Pharm. Biomed. Anal. 2014, 87:1-11. 10.1016/j.jpba.2013.08.041.
7. Blekherman G., Laubenbacher R., Cortes D.F., Mendes P., Torti F.M., Akman S., et al. Bioinformatics tools for cancer metabolomics. Metabolomics 2011, 7:329-343. 10.1007/s11306-010-0270-3.
8. Theodoridis G.A., Gika H.G., Want E.J., Wilson I.D. Liquid chromatography-mass spectrometry based global metabolite profiling: a review. Anal. Chim. Acta 2012, 711:7-16. 10.1016/j.aca.2011.09.042.
9. Lu W., Bennett B.D., Rabinowitz J.D. Analytical strategies for LC-MS-based targeted metabolomics. J. Chromatogr. B 2008, 871:236-242. 10.1016/j.jchromb.2008.04.031.
10. Kind T., Fiehn O. Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinforma. 2007, 8:105. 10.1186/1471-2105-8-105.
11. Smith C.A., O'Maille G., Want E.J., Qin C., Trauger S.A., Brandon T.R., et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 2005, 27:747-751.
12. Wishart D.S., Jewison T., Guo A.C., Wilson M., Knox C., Liu Y., et al. HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Res. 2013, 41:D801-D807. 10.1093/nar/gks1065.
13. NIST/EPA/NIH NIST Mass Spectral Library 2011, National Institute of Standards and Technology, USA, (n.d.).
14. Hoffmann T., Krug D., Hüttel S., Müller R. Improving natural products identification through targeted LC-MS/MS in an untargeted secondary metabolomics workflow. Anal. Chem. 2014, 86:10780-10788. 10.1021/ac502805w.
15. Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B. Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2015, 1000:95-104. 10.1016/j.jchromb.2015.07.021.
16. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044. 10.1126/science.1218595.
17. Willmann L., Erbes T., Halbach S., Brummer T., Jäger M., Hirschfeld M., et al. Exometabolom analysis of breast cancer cell lines: metabolic signature. Sci. Rep. 2015, 5:13374. 10.1038/srep13374.
18. Liebich H.M., Di Stefano C., Wixforth A., Schmid H.R. Quantitation of urinary nucleosides by high-performance liquid chromatography. J. Chromatogr. A 1997, 763:193-197.
19. Hua Y., Jenke D. Increasing the sensitivity of an LC-MS method for screening material extracts for organic extractables via mobile phase optimization. J. Chromatogr. Sci. 2012, 50:213-227. 10.1093/chromsci/bmr049.
20. Pluskal T., Castillo S., Villar-Briones A., Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinforma. 2010, 11:395. 10.1186/1471-2105-11-395.
21. Xia J., Mandal R., Sinelnikov I.V., Broadhurst D., Wishart D.S. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012, 40:W127-W133. 10.1093/nar/gks374.
22. Wolf S., Schmidt S., Müller-Hannemann M., Neumann S. In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinforma. 2010, 11:148. 10.1186/1471-2105-11-148.
23. Kind T., Liu K.-H., Lee D.Y., DeFelice B., Meissen J.K., Fiehn O. LipidBlast in silico tandem mass spectrometry database for lipid identification. Nat. Methods 2013, 10:755-758. 10.1038/nmeth.2551.
24. Hutschenreuther A., Kiontke A., Birkenmeier G., Birkemeyer C. Comparison of extraction conditions and normalization approaches for cellular metabolomics of adherent growing cells with GC-MS. Anal. Methods 2012, 4:1953. 10.1039/c2ay25046b.
25. Gaquerel E., Heiling S., Schoettner M., Zurek G., Baldwin I.T. Development and validation of a liquid chromatography-electrospray ionization-time-of-flight mass spectrometry method for induced changes in Nicotiana attenuata leaves during simulated herbivory. J. Agric. Food Chem. 2010, 58:9418-9427. 10.1021/jf1017737.
26. Bullinger D., Neubauer H., Fehm T., Laufer S., Gleiter C.H., Kammerer B. Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling. BMC Biochem. 2007, 8:25. 10.1186/1471-2091-8-25.
27. Barker M., Rayens W. Partial least squares for discrimination. J. Chemom. 2003, 17:166-173. 10.1002/cem.785.
28. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181. 10.1080/10408360500523878.
29. Owen J.B., Butterfield D.A. Measurement of oxidized/reduced glutathione ratio. Protein Misfolding and Cellular Stress in Disease and Aging 2010, 269-277. Humana Press, Totowa, NJ, (accessed 15.12.15). http://link.springer.com/10.1007/978-1-60761-756-3_18, P. Bross, N. Gregersen (Eds.).
30. Yeh C.-C., Hou M.-F., Tsai S.-M., Lin S.-K., Hsiao J.-K., Huang J.-C., et al. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin. Chim. Acta 2005, 361:104-111. 10.1016/j.cccn.2005.05.002.
31. Kanaan Y.M., Sampey B.P., Beyene D., Esnakula A.K., Naab T.J., Ricks-Santi L.J., et al. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteom. 2014, 11:279-294.
32. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948. 10.1056/NEJMra1001389.
33. Chiarugi A., Dölle C., Felici R., Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat. Rev. Cancer 2012, 12:741-752. 10.1038/nrc3340.
34. Denizot Y., Desplat V., Drouet M., Bertin F., Melloni B. Is there a role of platelet-activating factor in human lung cancer?. Lung Cancer 2001, 33:195-202.
35. Nigam S., Müller S., Benedetto C. Elevated plasma levels of platelet-activating factor (PAF) in breast cancer patients with hypercalcemia. J. Lipid Mediat 1989, 1:323-328.
36. Takayama T., Tsutsui H., Shimizu I., Toyama T., Yoshimoto N., Endo Y., et al. Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry. Clin. Chim. Acta 2016, 452:18-26. 10.1016/j.cca.2015.10.032.
37. Honn K.V., Bockman R.S., Marnett L.J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 1981, 21:833-864. 10.1016/0090-6980(81)90240-9.
38. Jaffe B.M. Prostaglandins and cancer: an update. Prostaglandins 1974, 6:453-461. 10.1016/S0090-6980(74)80055-9.
39. Rolland P.H., Martin P.M., Jacquemier J., Rolland A.M., Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 1980, 64:1061-1070.
40. Zhang T., Wu X., Yin M., Fan L., Zhang H., Zhao F., et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin. Chim. Acta 2012, 413:861-868. 10.1016/j.cca.2012.01.026.
41. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1185-1191.
42. Dong J., Cai X., Zhao L., Xue X., Zou L., Zhang X., et al. Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 2010, 6:478-488. 10.1007/s11306-010-0215-x.
43. Dória M.L., Cotrim Z., Macedo B., Simões C., Domingues P., Helguero L., et al. Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells. Breast Cancer Res. Treat. 2012, 133:635-648. 10.1007/s10549-011-1823-5.
44. Goto T., Terada N., Inoue T., Kobayashi T., Nakayama K., Okada Y., et al. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer: lysophosphatidylcholine and prostate cancer. Prostate 2015, 75:1821-1830. 10.1002/pros.23088.
45. Bullinger D., Fux R., Nicholson G., Plontke S., Belka C., Laufer S., et al. Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis. J. Am. Soc. Mass Spectrom. 2008, 19:1500-1513. 10.1016/j.jasms.2008.06.015.
46. Frickenschmidt A., Frohlich H., Bullinger D., Zell A., Laufer S., Gleiter C.H., et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008, 13:435-449. 10.1080/13547500802012858.
47. Henneges C., Bullinger D., Fux R., Friese N., Seeger H., Neubauer H., et al. Prediction of breast cancer by profiling of urinary RNA metabolites using support vector machine-based feature selection. BMC Cancer 2009, 9:104. 10.1186/1471-2407-9-104.